Highlights（Unaudited relevant data for the six months ended 29 February 2024）

• Revenue increased by 19.3% YoY to approximately RMB1,160.2 million;
• Gross profit rose by 17.5% YoY to approximately RMB578.0 million;
• Profit for the period attributable to owners of the Company rose by 13.2% YoY to approximately RMB338.2 million;
• Number of student enrolments increased by 12.3% over the corresponding period of last year to 96,100;
• Cash and cash equivalents amounted to RMB1,491.0 million, indicating ample liquidity;
• Interim dividend per share of 9.6 HK cents with a dividend payout ratio of 30%.

HONG KONG, Apr 26, 2024 – (ACN Newswire) – Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its unaudited FY2024 Interim Results for the six months ended 29 February 2024 (the “Reporting Period”). During the Reporting Period, by actively responding to national policies and closely following the market demand and industry development trends, the Group continued to increase its investment in school operations, deepened the integration of industry and education and school-enterprise cooperation, and continuously optimized the layout of vocational education disciplines, so as to realize sustainable development in the seamless connection of education and employment, thereby achieving steady improvement in results.

During the Reporting Period, the Group’s revenue was approximately RMB1,160.2 million, representing an increase of 19.3% over the corresponding period of the preceding year, mainly due to the increase in the number of students enrolled in the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 13.2% YoY to approximately RMB338.2 million. The Group’s cash and cash equivalents amounted to RMB1,491.0 million, indicating ample liquidity. The number of students enrolled in the Group’s schools continued to rise to new heights, reaching approximately 96,000. The Board of Directors of the Group has recommended the payment of an interim dividend of HK9.6 cents per share for the six months ended 29 February 2024, representing a dividend payout ratio of 30%.

From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;
Ms. Liu Wenqi, Chief Operating Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;
Mr. Liu Yuk Tung, Chief Financial Officer.

Optimizing the layout of vocational education disciplines and realizing the seamless integration of education and employment

In recent years, the Group has established its presence in the Guangdong-Hong Kong-Macao Greater Bay Area and the Chengdu-Chongqing Economic Circle, and expanded across the country and around the world. In line with the current trend and taking into consideration the industrial development and market demand, the Group has actively explored the new collaborative education model between “schools, communities and enterprises” to cultivate inter-disciplinary skilled application-oriented talents in high demand in the market. To address the talent demands of national strategic emerging industries and emerging innovative industries, the Group fully leveraged the advantages of its schools in multi-disciplinary development, covering economics, management, liberal arts, engineering, arts, education, science, and medicine, and improved the discipline layout by actively offering market-needed disciplines, such as artificial intelligence, cloud computing, big data, new energy, dentistry, animation and design, digital economics, etc. Meanwhile, with the aim of achieving a “seamless transition” from academics to employment and bridging the gap between on-campus education and internship, the Group has newly established digital commerce and industrial college, animation and gaming industry college, Guangdong rural leisure industry college and other colleges, etc., and has forged school-enterprise cooperation with over 1,000 large enterprises, including Huawei, CMGE, Bosch, Oracle, JD.com and iFLYTEK during the Reporting Period.

Closely following national policies and focusing on connotation development

Recognition of outstanding educational achievements

Since its establishment, the Group has actively responded to national policies, kept abreast of market demand and industry development trends, and continued to increase its investment in the running of schools. During the Reporting Period, Guangzhou Huashang Vocational College was successfully approved to set up the Doctoral Workstation of Guangdong Province, making it the only private higher vocational college among the batch of approved organizations. Meanwhile, by strengthening teacher training, raising teacher remuneration, optimizing teacher appraisal mechanisms and other measures, the Group provides solid guarantees for the high-quality development of its schools. In addition, the Group has also embarked on campus construction, renovation and upgrading of training facilities and equipment to create a high-quality educational environment and realize a steady improvement in benefits. With optimized connotation development, the operational strengths of the Group’s colleges has also improved significantly, enabling the Group to deliver outstanding educational performance. During the Reporting Period, a new breakthrough was achieved again in the construction of first-class program at Guangzhou Huashang College, with a total of seven programs selected as first-class undergraduate programs at the provincial level. Guangzhou Huashang Vocational College was awarded the “National Exemplary Vocational College of 2023” by Tencent News on the basis of unique teaching concepts and outstanding educational achievements, and Urban Vocational College of Sichuan was ranked fourth in China and first in Sichuan in the 2024 GDI Top 100 Private Higher Vocational Colleges, and ranked ninth in China and first in Sichuan in terms of the number of scientific research projects launched by higher vocational education colleges in 2023. Therefore, it can be seen that through the continuous improvement in connotation development, the Group’s colleges have been able to reap greater synergies and build a stronger reputation for school operations. High-quality education has also become a strong driver for promoting sustainable and healthy growth in the Group’s results.

Future Prospects

Looking ahead, with strong government policy support and over 20 years of experience in private education, the Group will continue to deepen the integration of industry and education and school-enterprise cooperation, and keep pace with the development of the country’s strategic emerging industry clusters. Driven by the development of core disciplines and discipline groups, the Group will vigorously develop new and cross-disciplines, such as artificial intelligence, digital economy, financial science and technology, healthcare and elderly care, etc. In order to promote the optimization and upgrading of the schools’ disciplines and cultivate a new generation of high-quality and application-oriented talents with international vision, thus making positive contributions to laying a solid foundation of talents for the realization of national strategic goals and promoting the high-quality development of vocational education.

About Edvantage Group Holdings Limited

Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,100 as of 29 February 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.

While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance, the “ESG Leader Award” from Gelonghui, and the “Highest Investor Attention Award” from Huashengtong in 2023.

Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HO CHI MINH CITY, VIETNAM, Apr 26, 2024 – (ACN Newswire) – Imexpharm Corporation (“Imexpharm” or the “Company,” IMP.VN), a pioneering leader in Vietnam’s pharmaceutical industry, announced that its 2024 Annual General Meeting of Shareholders (AGM) was held today at the Hilton Saigon Hotel, District 1, Ho Chi Minh City.

Ms. Chaerhan Chun, Non-Executive Chairman of Imexpharm’ s Board of Directors, said, “In 2023, Imexpharm met head on the challenges created by the complex macro environment, including inflation, geoeconomic fragmentation, geopolitical instability and climate change, and reported its best performance since listing in 2006.”

Ms. Tran Thi Dao, General Director of the Executive Board, and Executive Director of Imexpharm’ s Board of Directors commented, “We are delighted with Imexpharm’ s performance. Our decades of investing in technology such that we have the largest number of EU-GMP production lines, has given us a strong competitive advantage in the hospital channel, which has helped to drive our record-breaking growth in 2023.”

2023 was a record-breaking year for Imexpharm. The Company’s total revenue increased by 26% YoY to to VND2,113.0 billion. This represents a record year of growth for the Company, and compares favourably to overall market growth of 8%. EBITDA jumped 31% to end the year at VND466.0 billion, significantly ahead of the Company’s budgeted numbers. Over the past five years, Imexpharm’s EBITDA CAGR has been an impressive 17.5%.

Throughout 2023, Imexpharm maintained its leading position for the production and distribution of antibiotics in Vietnam, boasting a market share approaching 9%. At the same time, the Company’s diversification initiatives yielded robust revenues from various product categories, notably cough medications, analgesics, antipyretics and digestive aids. Furthermore, Imexpharm strategically expanded its revenue streams by venturing into the lucrative segments of vitamins and health supplements, aligning with the growing wellness market.

With its commitment to meeting evolving consumer demands through product diversification, Imexpharm embarked on exploring international markets in 2023. The Company is well positioned strategically to extend its sales footprint into diverse markets across Asia and Europe. This is thanks to its international-standard Safety, Health, Environment (SHE) protocols and Maintenance, Repair, Operations (MRO) standards, in addition to the 27 European Union Marketing Authorizations (MAs) it holds.

To express its gratitude for shareholders’ ongoing support, the Board of Directors of Imexpharm will implement a new dividend policy for 2024/2025, increasing it to 20%, with 10% in the form of a cash dividend and 10% in stock dividends. The resolution to approve this was successfully passed at today’s AGM.

Looking into 2024, despite the challenging macroeconomic environment, Vietnam and the domestic pharmaceutical industry are expected to continue to grow. The IMF is forecasting that Vietnam will be the world’s 20th fastest growing economy. Reflecting its ambitions for the economy, the National Assembly has set a 2024 GDP growth target for Vietnam of 6.0-6.5%, more than double the IMF’s expectations for that measure globally.

While the Vietnamese pharmaceutical sector is expected to grow by 6% to 8% over the year, Imexpharm is committed to double-digit growth. Following its record-breaking year in 2023, Imexpharm is targeting gross revenue growth of 24% in 2024. Within this, the Company expects to achieve robust revenue growth in the fast-growing ETC sales channel of 49%. The Company also aims to further boost its EBITDA by 18%.

Imexpharm recently reported revenue growth for Q1 2024, despite a complex operating environment inevitably impacting performance during the quarter.  The systems and processes put in place by the Company to handle market fluctuations, as well as its plans for new products and new markets, mean Imexpharm is confident in meeting its targets for the year ahead.

Ms. Chaerhan Chun said, “Doing business in a highly competitive and continuously changing pharmaceutical sector is not easy.  This makes me incredibly proud of Imexpharm’ s many achievements during 2023.  This coming year, we will continue to meet all challenges head on, flexing our business model to meet customer demand and to deliver on the promises we have made today to our shareholders.”

Ms. Tran Thi Dao commented, “2024 is another challenging year ahead, but we are prepared for this, and have a robust growth plan for delivering another record year of results. We will continue to expand our revenues aggressively and are seeing terrific growth particularly in the ETC channel. Our factories, including our newest IMP4 factory, are gearing up production to meet the high levels of demand we have from our customers. As we continue to diversify our products and look to grow in new markets, I am excited about our next phase of growth ahead.”

About Imexpharm

Imexpharm is a market leader in manufacturing and distributing high quality antibiotics in Vietnam. Over its close to fifty-year history, the company has been a pioneer in Vietnam’s rapidly evolving pharmaceutical industry, focusing on international partnerships and operating at the highest safety and quality standards.  Looking to the future, it is strategically and financially poised for growth domestically and on the global stage, and has been, and will continue to expand its portfolio into new treatment areas and wellness.

For more information, please contact:

Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HONG KONG, Apr 25, 2024 – (ACN Newswire) – Black Spade Capital Limited (“Black Spade”), the family office of Mr. Lawrence Ho, is delighted to announce its donation of a stunning art and jewellery collection to the Hong Kong Red Cross (“Red Cross”). The gift represents Mr. Ho’s and Black Spade’s commitment to social responsibility and its unwavering dedication to creating a positive impact on the community.

The collection, comprising an array of 43 precious pieces from fine jewellery such as necklaces, pendants, brooches, jade to rare coins and stamps, highlights exceptional craftmanship and exquisite design. Whether these items showcase how Chinese culture is fused into everyday life through wearable art, or bear witness of momentous world events over the past several decades, they symbolise cultural heritage and are true embodiment of timeless elegance.

Mr Dennis Tam, President and CEO of Black Spade, said, “Black Spade is honoured to contribute this extraordinary collection to Red Cross. Red Cross has been serving the community since 1950 with a reputable track record of providing emergency relief and humanitarian aid. We firmly believe in the power of collective action to bring about meaningful change, and we are confident that this donation will make a significant difference in the lives of those in need. We hope that our contribution will inspire others to join us in our mission to create a brighter and more equitable future for all.”

Dr Lau Chor Chiu, Chairperson of the Hong Kong Red Cross, stated, “We sincerely thank Mr. Lawrence Ho and Black Spade for their generous donation. The Hong Kong Red Cross will use these art collections to support its fundraising efforts and further advance our humanitarian work, such as providing emergency disaster relief and preparedness, community health, humanitarian engagement, and special education and rehabilitation services for vulnerable communities. We hope this inspiring act of generosity will encourage more individuals and organizations to support our work and act together to build a safer, healthier and more cohesive community.”

Photo caption:

From the left: Mr. Dennis Tam, President and CEO of Black Spade and Dr Lau Chor Chiu GMSM, MH, JP, Chairperson of the Hong Kong Red Cross

About Black Spade Capital Limited

Black Spade Capital Limited is an established family office that manages the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade’s investment strategy maximizes coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, medical technology, leisure and culture, green energy, real estate to Pre-IPO investments. In August 2023, Black Spade Acquisition Co, a blank check company (SPAC) sponsored by Black Spade, completed a US$23 billion business combination with VinFast Auto Ltd.

About the Hong Kong Red Cross

Established in 1950, the Hong Kong Red Cross is part of the International Red Cross and Red Crescent Movement and the world’s humanitarian network serving over 190 countries. It dedicates itself to motivating people from all walks of life to put humanitarian spirit into action. With services in four main areas, namely, “Emergency Relief and Disaster Preparedness”, “Community Health Service and Education”, “Humanitarian Engagement and Education”, and “Special Education and Rehabilitation”, it provides a diversified humanitarian platform for Hong Kong citizens. Please visit www.redcross.org.hk for details.

Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HONG KONG, Apr 17, 2024 – (ACN Newswire) – China Isotope & Radiation Corporation (“CIRC” or the “Company” , together with its subsidiaries, the “Group”; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 (“2023” or the “Reporting Period”).

For the year ended 31 December 2023, the Group operated five business segments, namely pharmaceuticals, radioactive source products, irradiation, radiation therapy equipment and related services and other businesses. In 2023, the Group continued to intensify our market development efforts and achieved continued growth in economic efficiency. For the year of 2023, the Group recorded revenue of RMB6.635 billion, representing a year-on-year increase of 7.8%; gross profit was RMB3,482.2 million, gross margin was 52.5%; realized net profit of RMB776.1 million, representing a year-on-year increase of 2.8%, with net profit attributable to the parent company achieving RMB371.0 million.

Pharmaceutical segment: Magnificent development in existing industries and businesses with steady expansion of industry influence

In 2023, in respect of pharmaceutical segment, the Group provided a stable supply of radiopharmaceuticals to domestic medical institutions and strengthened the promotion of nuclear medicine diagnosis and treatment technology to clinical departments and other market development work, while continuously promoting development in existing industries and businesses. Through academic conferences and other means, the Group conducted scientific popularization for the general public and nuclear medicine clients on new products such as “therapeutic sodium iodine-131 capsule” and scientific radionuclide, enhancing its influence in the field of nuclear medicine. In December 2023, therapeutic sodium iodine-131 capsule manufactured by HTA Co., Ltd., a subsidiary of the Group, has successfully entered the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023) as a drug covered by the national medical insurance negotiations.

During the Reporting Period, the Group recorded RMB4,128.6 million in revenue from sales of pharmaceuticals, representing a year-on-year increase of 5.2%, accounting for 62.2% of the total revenue, recorded RMB1,682.8 million in revenue from imaging diagnostic and therapeutic radiopharmaceuticals, representing a year-on-year increase of 15.3%, and recorded RMB2,323.8 million in revenue from breath test.

Radioactive source products business: Successfully providing service for the Shenzhou XV manned spacecraft and remaining a high market share

In 2023, the supporting radioactive source developed by the Group for the Shenzhou XV manned spacecraft performed satisfactorily during the mission by ensuring accurate ignition command of the thrust reverser engine by the Y-altitude control device and safe and soft landing of the returning capsule, thereby guaranteeing the successful completion of Shenzhou XV manned mission. The technology of reusing retired radioactive source has made outstanding contributions in the field of applied research on circular economy, and won the First Prize of Sichuan Province Low Carbon Science and Technology Award. During the Reporting Period, a new type of domestically produced krypton [85kr] thickness gauge sources was officially launched into the market.

During the Reporting Period, the Group recorded RMB586.2 million in revenue from radioactive source products, representing a year-on-year increase of 0.9%. Gamma knife source and non-destructive testing radioactive source remained a stable and high market share, achieving growth in revenue, of which, gamma knife source realized operating revenue of RMB73 million and non-destructive testing radioactive source realized operating revenue of RMB89 million.

Irradiation business: Continuously innovating the mode of cooperation and sales revenue of new products reaching a record high

In 2023, the Company made innovation in the mode of cooperation and made deep-seated efforts to lay out its business in and explore EB curing industry, resulting in completion of technique and production line of EB plates, while arranging for EB color-coated plates and EB film so as to build EB curing industrial ecosystem. BINE High-Tech Co., Ltd., a subsidiary of the Group, successfully completed the after-sales maintenance for the 4 million curies BFT gamma irradiation equipment of Grand Ten Holdings in Malaysia, which is the first export project of BINE High-Tech Co., Ltd. and has maintained safe operation for 10 years without any incident.

During the Reporting Period, the Group actively explored the irradiation product market, with sales revenue of new irradiation products soaring to over RMB28.5 million, reaching a record high. The Group recorded RMB170.8 million in revenue from irradiation-related business.

Radiation therapy equipment and related services: Accelerating domestic manufacturing process of high-end radiotherapy equipment and the first product has successfully obtained approval

In 2023, the Group accelerated domestic manufacturing process of high-end radiotherapy equipment. On 28 September 2023, CNNC Accuray (Tianjin) Medical Technology Co., Ltd. (“CNNC Accuray”), a subsidiary of the Group, successfully obtained the medical device registration certificate issued by the National Medical Products Administration for its domestic high-end spiral tomotherapy system (TOMO C). This product has become the first domestic spiral tomotherapy product in the high-end medical field in China. The official mass production launch event and investor exchange meeting of TOMO C was held in Tianjin on 25 October.

In addition, CNHE-MDR, the outcome of the mobile digital medical X-ray photography system research and development project, was approved in June 2023 and obtained the medical device registration certificate. The Smart Cobalt-60-based Cone Beam Focused Stereotactic Therapy System project has completed the product type testing and entered the clinical trial stage smoothly. The SPECT/CT project has passed the general inspection and acceptance of the State Administration of Science, Technology and Industry for National Defence, with an acceptance rating of “excellent”.

During the Reporting Period, the Group recorded RMB933.7 million in revenue from nuclear medical equipment and related services, representing a year-on-year increase of 27.5%, and accounting for 14.1% of total revenue, making it the second largest source of revenue.

International business: Gradually deepening the global presence and making breakthroughs in a number of businesses

During the Reporting Period, the Group robustly explored the international market and exported breath test kits, radioimmunity kits, radiopharmaceuticals dispensing equipment, medical equipment and devices as well as other products to dozens of countries and regions such as Indonesia, Brazil, Peru, Colombia, Ecuador, India, Bangladesh, Singapore and Vietnam, realizing a total export revenue of RMB430 million. International business revenue from regular medical products maintained significant growth in 2023.

Marketing: Promoting brand building in an orderly manner and fully utilizing the value of the IAEA platform

During the Reporting Period, the Group deepened its brand building efforts. In May 2023, the Group successfully organized the “Sichuan Medical Isotopes and Radiopharmaceutical Industry Development Promotion Summit” in conjunction with eight departments in Sichuan Province. In September 2023, the Group contributed to and participated in the Conference on the High-quality Development of the Nuclear Technology Application Industry, the 2nd China-ASEAN Forum for Peaceful Use of Nuclear Technology, and etc. where the Group launched cooperation demonstration projects, signed business cooperation documents, and displayed nuclear medical equipment and digital exhibits for nuclear medicine. The Group participated in the Academic Annual Conference of the Nuclear Medicine Branch of the Chinese Medical Association in 2023 to launch the Radiant Intelligence 1.0 Intelligent Nuclear Medicine System, and co-hosted the 2nd International Forum on the Development of Nuclear Technology Application Industry in October 2023, fully demonstrating the CIRC’s leadership in nuclear technology application industry.

Furthermore, the Group has been actively leveraging the value of the IAEA Collaboration Center platform to enhance its international influence. In August 2023, the Group hosted the “International Training Course on Radiopharmaceuticals Preparation for the Asia-Pacific Region” in the name of the IAEA Collaboration Center for Radiopharmaceuticals and Radioactive Sources. The Group has persisted in reform of its marketing center to foster the synergistic, high-quality and safe development of its business in radiopharmaceuticals, radioactive sources and radioactive particles. In respect of the marketing of domestic nuclides, internal resources were coordinated and integrated for production, sales, distribution and services of domestic Lu-177 and Ge/Ga generators, laying the foundation for market development after reaching design capacity thereof in 2024.

Scientific research and innovation: Multiple projects conducting clinical trial and work related to intellectual properties gaining significant progress

The Group has always actively conducted research and development work on various types of imaging diagnosis and therapeutic pharmaceuticals to fill gaps in various fields of medical treatment and meet the medical needs of China. As of 31 December 2023, the Group had a number of imaging diagnosis and therapeutic radiopharmaceuticals under research and development. Among them, sodium fluorine injection has completed clinical trials and was submitted for new drug application; iodine-MIBG injection was in Phase III clinical trial; technetium sulfide colloidal injection, Ga-Dotatate injection, fluorine betazine injection, fluorine stamine injection, fluorine-L dopa injection and lutetium oxyoctreotide injection were approved for the clinical trial, and a variety of imaging diagnosis and therapeutic radiopharmaceuticals were in preclinical research and development stage.

During the Reporting Period, the Group yielded remarkable results in the work related to intellectual properties, with a total of 298 patents applied, 240 patent authorizations obtained, including 5 foreign design patent authorizations. As of 31 December 2023, the Group had 945 active licensed patents, among which there were 149 invention patents, sustaining and enhancing its technological strength. the Company had 11 registered trademarks, 38 registered copyrights, 1 national standard, 1 energy industry standard and 6 group standards issued, and 1 national standard, 1 agricultural industry standard, 4 nuclear industry standards and 12 group standards under preparation/to be released.

In terms of technological awards and honors, during the Reporting Period, the Group won 1 provincial and ministerial technology award, 4 social science and technology awards, 1 group-level science and technology award, and 3 awards in the CNNC Science and Innovation Competition.

Outlook

Looking ahead, CIRC will give full play to the unique advantages of nuclear medicine in the diagnosis and treatment of major diseases such as neurodegenerative diseases, cardiovascular and cerebrovascular diseases and malignant tumors, and provide quality products, services and integrated solutions to better protect people’s lives and health and facilitate the construction of “Healthy China”.

In 2024, the Company will firmly grasp the development opportunities, spare no effort, to maintain a good growth momentum, make every effort to drive the economic performance to a record high and practically improve the innovation and value creation capabilities, continuously strengthen the core functions and enhance the core competitiveness, and perform the three major roles of scientific and technological innovation, industry control, and safety support, in order to accomplish the planning objectives and tasks and accelerate the establishment of an internationally renowned isotope and radiation technology application products and services supply group.

About China Isotope & Radiation Corporation

China Isotope & Radiation Corporation (referred as “CIRC” or “the Company”) since its establishment in 1983, has been dedicated to exploring and developing nuclear technology applications. Boasting over 40 years of industry experience, the Company has emerged as a prominent leader in the domestic nuclear technology industry. The Group is primarily engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radio pharmaceuticals and radioactive source products for medical and industrial applications, the provision of irradiation service for sterilization purpose and engineering, procurement and construction (“EPC”) service for the design, manufacturing and installation of gamma ray irradiation facilities and the provision of nuclear medical equipment and services such as independent clinical laboratory services to hospitals and other medical institutions.

The nuclear medicine industry is an industry with immense potential, demanding threshold, and high returns. As a leader in China’s nuclear medicine industry, CIRC is the largest domestic manufacturer of imaging diagnostic and therapeutic radiopharmaceuticals, UBT diagnostic kits and test analyzers, as well as radioimmunity analysis kits. In field of radioactive source products, it is the only core enterprise in the field of radioactive source research and application that has industrialized and scaled research and production capabilities. In field of radiation, it is the third largest radiation processing service provider in China, and the only supplier in China that provides upstream production and downstream design and installation services for radiation equipment. And two of its subsidiaries have been approved by the Ministry of Ecology and Environment of the People’s Republic of China as two of the three EPC service providers authorized to engage in the design, manufacturing, and installation of radiation equipment.

Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com